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Neutrophil granulocytes have the shortest lifespan among leukocytes in the circulation and die
via apoptosis. At sites of infection or tissue injury, prolongation of neutrophil lifespan is critical
for effective host defense. Apoptosis of inﬂammatory neutrophils and their clearance are critical
control points for termination of the inﬂammatory response. Evasion of neutrophil apoptosis
aggravates local injury and leads to persistent tissue damage. The short-lived prosurvival Bcl-
2 family protein, Mcl-1 (myeloid cell leukemia-1), is instrumental in controlling apoptosis and
consequently neutrophil lifespan in response to rapidly changing environmental cues during
inﬂammation. This paper will focus on multiple levels of control of Mcl-1 expression and function
and will discuss targeting Mcl-1 as a potential therapeutic strategy to enhance the resolution of
inﬂammation through accelerating neutrophil apoptosis.
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1. INTRODUCTION
Neutrophils or polymorphonuclear leukocytes are the most abundant cells of the innate immune system
and form the ﬁrst line of defence against invading pathogens. Circulating neutrophils have a very short
half-life because they constitutively undergo apoptosis and are functionally quiescent [1–3]. Neutrophil
lifespan is dynamically inﬂuenced during the course of inﬂammatory response by multiple signals from
the inﬂammatory microenvironment [3–5]. Recruitment of neutrophils into infected or injured tissues
is associated with prolongation of their lifespan through delaying apoptosis, which allows performing
their antimicrobicidal function effectively [6, 7]. Shortened neutrophil survival enhances susceptibility
to recurrent infections under some pathological conditions [8, 9]. Elimination of the offending insult
ideally prompts resolution of inﬂammation. Emigrated neutrophils undergo apoptosis and are removed
by scavenger macrophages [10]. Excessive or dysregulated neutrophil responses together with inadequate
repair contribute to persisting tissue damage that underlies many inﬂammatory diseases [2, 11–13]. Efﬁcient
resolution of inﬂammation therefore relies on inhibition of neutrophil inﬂux, recruitment of monocytes,
rapidclearanceofinﬁltratingneutrophils,andregenerationofdamagedtissuestructures[14,15].Neutrophil
survival/apoptosis emerged as one of the control points in resolving inﬂammation. Neutrophil apoptosis is
tightly regulated by a complex network of signalling pathways that controls expression and degradation
of key molecules, including Bcl-2 family proteins, activation of MAP kinases, NF-κB, and caspases
[1, 3, 4]. One of the distinguishing features of neutrophil apoptosis is the preeminence of the Bcl-2
homolog Mcl-1 as a survival protein [16, 17]. In general, Mcl-1 expression inversely correlates with
the degree of neutrophil apoptosis in both experimental models and clinical settings. Mcl-1 has some
unusual properties compared with other Bcl-2 family members, including an extremely high turnover rate
[18, 19], which is well suited for dynamic control of neutrophil survival. Understanding the molecular
mechanisms that control Mcl-1 turnover and function may provide a rational basis for development of
novel therapeutic approaches to modulate neutrophil apoptosis and consequently to facilitate resolution of
neutrophil-mediated inﬂammatory diseases.
2. NEUTROPHIL APOPTOSIS IN HUMAN DISEASE
2.1. The Fate of Neutrophils
Under physiological conditions, circulating mature neutrophils are generally thought to have a lifespan
<1d a yin vivo [20, 21] though a recent study using in vivo labelling reported 10 times longer lifespan
[22]. Circulating neutrophils are thought to undergo constitutive apoptosis and home to the spleen, liver, or
back to the bone marrow to be destroyed by macrophages [3, 23]. This mechanism is essential to keep the
balance of cellular homeostasis [1]. Circulating neutrophils are rapidly recruited into infected or injured
tissues. Outside-in signalling through the β2 integrin Mac-1 during endothelial transmigration [24]o r
exposure of neutrophils to inﬂammatory mediators profoundly inﬂuences neutrophil survival and death
[1, 3]. Among the inﬂammatory mediators, granulocyte-macrophage colony-stimulating factor (GM-CSF)
and IL-8, bacterial constituents, such as LPS and bacterial DNA containing unmethylated CpG motifs, or
the acute-phase reactants C-reactive protein and serum amyloid A can prolong the longevity of neutrophils,
whereas proapoptotic stimuli, such as TNF-α, TRAIL (TNF-related apoptosis-inducing ligand), or Fas
ligand shorten their lifespan [25–29]. Phagocytosis of invading microorganisms triggers programmed cell
death in neutrophils [30]. Apoptosis renders neutrophils unresponsive to extracellular stimuli, prevents
release of toxic constituents, and facilitates their recognition and clearance by macrophages [10, 31].
Since, under most conditions, neutrophils will be exposed to multiple mediators, their fate would ultimately
depend on the balance between prosurvival and proapoptotic cues (reviewed in [5]). Precise control of the
neutrophil death program provides a balance between their defence functions and safe clearance, whereas
impaired regulation of neutrophil death is thought to contribute to a wide range of inﬂammatory pathologies
[2, 11, 12].
1949TheScientiﬁcWorldJOURNAL (2011) 11, 1948–1962
2.2. Altered Neutrophil Survival/Apoptosis in Human Disease
Neutrophil death is tightly regulated on a constitutive basis, and the complexity increases under pathological
conditions, so that it is often difﬁcult to decide whether survival or apoptosis is most favourable from the
host’sperspective.Indeed,bothacceleratedanddelayedneutrophilapoptosiscouldhaveseverepathological
consequences. For instance, pyocyanin produced by the opportunistic pathogen Pseudomonas aeruginosa
[32], inﬂuenza virus A [33], and HIV [8] shortens neutrophil longevity by accelerating apoptosis, leading to
impaired antimicrobial defences and increased susceptibility to recurrent infections. Upregulation of Fas is
thought to contribute to accelerated neutrophil apoptosis in patients with systemic lupus erythematosus [34].
A wide variety of inﬂammatory diseases, including acute respiratory distress syndrome (ARDS),
pneumonia, sepsis, acute coronary artery disease, rheumatoid arthritis, and cystic ﬁbrosis, is associated
with delayed neutrophil apoptosis in the blood, sputum, or synovial ﬂuid [35–40]. A frequent ﬁnding in
these studies is the correlation of neutrophil apoptosis with the severity and/or outcome of the disease.
Various mechanisms have been implicated in suppression of neutrophil apoptosis. For example, enhanced
GM-CSF production is thought to prolong neutrophil survival in sepsis [35], severe burns [36], ARDS
[37], or acute coronary artery disease [38], whereas NF-κB-mediated survival cues have been implicated
in chronic obstructive pulmonary disease and respiratory syncytial virus infection-associated delay of
neutrophil apoptosis [39, 40]. Lactoferrin released from activated neutrophils [41] and serum amyloid
A[ 42] have been implicated in increased neutrophil longevity in rheumatoid arthritis. Resistance to Fas
ligand-triggered apoptosis and direct inhibition of caspase-3 by acrolein, a toxic unsaturated aldehyde found
in cigarette smoke, has also been implicated in suppression of neutrophil apoptosis [43, 44]. Intriguingly,
intracellular pathogens may use apoptotic neutrophils as a Trojan horse to promote infection [45, 46].
2.3. Bcl-2 Family Proteins in Human Neutrophils
Neutrophils constitutively express the proapoptotic members of the Bcl-2 family, including Bax, Bad, Bak,
Bid, and Bik [47]. These proteins have relatively long half-lives, and their cellular levels change very little
during exposure of neutrophils to agents that either accelerate or delay apoptosis. Human neutrophils
also express the antiapoptotic proteins Mcl-1, A1, and to a much lesser extent Bcl-XL, but not Bcl-2
[48]. Mcl-1 and to a lesser extent A1 appear to be important for maintaining cytokine-regulated survival
[17, 49] and have been implicated in signalling extended neutrophil lifespan in response to a variety of
proinﬂammatory stimuli [50–52]. Survival of myeloid cells markedly decreases following treatment with
antisense oligonucleotides against Mcl-1 [53]. Increased Mcl-1 expression has been detected in neutrophils
isolated from patients with Crohn’s disease [54] and severe sepsis [55].
3. REGULATION OF NEUTROPHIL APOPTOSIS BY Mcl-1
The mechanisms that govern neutrophil death have been extensively reviewed [3–5, 56]. Apoptosis may
resultfromactivationoftheextrinsic,intrinsic,orendoplasmicreticulumstresspathways[3,57].Acomplex
network of intracellular death/survival signaling pathways regulates neutrophil apoptosis, and the balance
of these circuits would ultimately determine the fate of neutrophils. There is now evidence that suggests
existence of hierarchy among these signals [5, 57]. For instance, ligation of Mac-1 integrates life and death
decisions in a ligand-speciﬁc manner [11, 30]. Mac-1-mediated phagocytosis of opsonized bacteria triggers
apoptosis [58, 59], whereas the binding of Mac-1 to ICAM-1, ﬁbrinogen [30], or myeloperoxidase [11]
prolongs the lifespan of neutrophils by suppressing apoptosis. Likewise, the pleiotropic receptor formyl
peptide receptor 2 (formyl-peptide-like-1 receptor/lipoxin receptor or FPR2/ALX) [60] generates opposing
signals to suppress or activate the apoptotic machinery following binding of one of its many ligands,
including serum amyloid A, the anti-inﬂammatory lipids lipoxin A4 and aspirin-triggered 15-epi-LXA4,
annexin A1, and the antimicrobial cathelicidin peptide human CAP18/LL37 [27, 60–63]. Many survival
and proapoptotic signalling pathways converge to inﬂuence expression of Mcl-1, which is central for
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maintaining neutrophil survival. Loss of Mcl-1 together with direct activation of the proapoptotic protein
Bax by calpain-1 [64] is likely responsible for rapid apoptosis. Indeed, neutrophil aging is associated
with decreased expression of calpastatin, a speciﬁc inhibitor of calpain-1, resulting in increased calpain-
1 activity.
3.1. Properties of Mcl-1
The human Mcl-1 gene is located on chromosome 1q21 and comprises three exons [65, 66]. The
prototypical Mcl-1 protein (also referred as Mcl-1L) comprises 350 amino-acid residues and contains three
BH (Bcl-2 homology) domains (BH1-3), which confer the ability to heterodimerize with other family
members [67]. Unlike Bcl-2 and Bcl-XL, Mcl-1 and A1 lack the N-terminal BH4 domain. Mcl-1 contains
a C-terminal transmembrane domain that serves to localise Mcl-1 to the mitochondrial outer membrane
and other intracellular membranes [68]. The N-terminal region contains PEST domains, rich in proline
(P), glutamic acid (E), serine (S), and threonine (T), and four Arg:Arg motifs that target Mcl-1 for rapid
turnover by the proteasome. Indeed, the half-life of the mature protein is estimated to be between 1 and 5
hours [69, 70].
Mcl-1 promotion of neutrophil survival is thought to involve heterodimerisation with and
neutralisation of proapoptotic Bcl-2 family proteins Bim or Bak in the mitochondrial outer membrane
[71, 72]. This leads to suppression of cytokine c release from mitochondria and Apaf-1-dependent activation
of caspase-3. Loss of mitochondrial transmembrane potential (  m) precedes development of apoptotic
morphology in neutrophils undergoing constitutive [73] or induced apoptosis.
3.2. Transcriptional Control of Mcl-1 Expression
The promoter region of Mcl-1 contains an array of putative and conﬁrmed transcription binding sites,
including consensus STAT response elements, cAMP response elements (CRE), and NF-κB binding sites
[74]. In a variety of cancer cells, transcription of Mcl-1 has been reported to be induced by cytokines, such
as IL-3, IL-5, IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF), growth factors, and
hypoxia-inducible factor 1α under hypoxic conditions (reviewed in [66]). GM-CSF also stimulates Mcl-1
transcription in human neutrophils, but these changes were disproportionately small compared with changes
at the protein level [47, 74, 75], suggesting a limited role for transcriptional regulation of Mcl-1 in cytokine-
mediated neutrophil survival. GM-CSF does not appear to signal through NF-κB[ 76]. G-CSF continues to
affect longevity of mature neutrophils at transcriptional level during in vivo mobilization of granulocytes for
transfusion purposes [77]. Hypoxia has been reported to delay neutrophil apoptosis [52, 78, 79] though the
role for HIF-1α modulation of Mcl-1 transcription remains to be investigated. NF-κB has been proposed to
play an important role in neutrophil survival [80], but curiously, there is no evidence for NF-κB regulation
of Mcl-1 transcription in these cells.
Downregulation of Mcl-1 mRNA is largely due to inactivation of transcription factors that stimulate
Mcl-1 transcription [66]. Another mechanism is direct repression of the Mcl-1 promoter by the transcription
factor E2F1, a key cell cycle regulator [81]. However, the function and activation of E2F1 in neutrophils are
largely unknown.
3.3. Posttranscriptional, Translational, and Posttranslational Control
In addition to transcriptional regulation, Mcl-1 is also subject to posttranscriptional, translational, and
posttranslational control. By removing exon 2, alternative splicing of Mcl-1 mRNA produces a shortened
formofMcl-1,Mcl-1S,whichlacksBH1,BH2,andthetransmembranedomain[66].Anothersplicevariant,
Mcl-1ES, lacks a portion of exon 1 but retains all three BH domains and the C-terminal transmembrane
domain [82]. These splice variants are unable to bind and sequester proapoptotic Bcl-2 family members;
indeed, they induce apoptosis by inhibiting full-length Mcl-1 [83]. Accumulation of Mcl-1S has been
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detected in macrophages during bacterial clearance, and this appears to regulate macrophage commitment
to apoptosis, likely facilitating the resolution of inﬂammation [84]. At the present time, no information is
available whether Mcl-1S is also generated in aging neutrophils.
The rate of Mcl-1 mRNA transcription is tightly regulated, and Mcl-1 mRNA, like the protein, has
a very short half-life [66]. Enforced expression of the microinhibiting RNA 29b (Mir-29b) was found to
reduce Mcl-1 translation and to induce apoptosis in malignant cholangiocarcinoma cells [85].
Posttranslational modiﬁcations can also modify the stability and function of Mcl-1. Sequence
analysis and mutational analysis of Mcl-1 revealed several potential phosphorylation sites in the PEST
domains, which may mediate complimentary or opposing processes (reviewed in [66]). For instance, cyclin-
dependent kinase 1 (CDK1), CDK2, or JNK-mediated phosphorylation of Ser64 appears to be required
for dimerisation with other Bcl-2 homologues and antiapoptotic function without affecting stability [86].
Phosphorylation of Thr92 (in conjunction with Thr163) by ERK-1 stabilizes Mcl-1 and is likely required
for antiapoptotic function [87]. Glycogen synthase kinase-3 (GSK3) phosphorylates Ser155, in conjunction
with Ser159 and Thr163, resulting in destabilization and impaired antiapoptotic function of Mcl-1 [88–90].
Ser121 is a target for JNK and p38 MAPK, and phosphorylation of this residue has been reported to either
inactivate or stabilize Mcl-1, most likely representing differences in the cell lines studied. One should recall
that since most of these studies were performed in tumor cells, it is uncertain whether these mechanisms
are also operational in neutrophils. Contradictory results have been reported for p38 MAPK in human
neutrophils; its action on neutrophil survival may be stimulus and/or context speciﬁc (reviewed in [48]).
Prosurvival function of p38 MAPK may include phosphorylation and inactivation of caspase-3 and caspase-
8[ 91], whereas in other studies, constitutive neutrophil apoptosis was found to be associated with prolonged
phosphorylation of p38 MAPK [27, 28, 92].
3.4. Intracellular Localisation
Under resting conditions Mcl-1, is localized to the cytoplasm, presumably as a heterodimer with Bax
and/or Bad, the outer mitochondrial membrane [68], the nuclear envelop [52], and the nucleus [93, 94].
Concomitant activation of the MEK/ERK 1/2 and phosphoinositide-3-kinase (PI3K)/Akt pathways by
proinﬂammatory mediators or ligation of Mac-1 [11, 27, 48, 92] results in phosphorylation of Bax and
Bad, leading to dissociation of Mcl-1 from phosphorylated Bad or Bax in the cytoplasm. This permits
targeting of Mcl-1 to the mitochondria, where it counters the activity of Bak and Bim [95]. Akt-mediated
phosphorylation of Bax at Ser184 promotes heterodimerization with Mcl-1 or A1 [96]. Interaction of Mcl-
1 with CDK1 and proliferating cell nuclear antigen (PCNA) is thought to be responsible for its nuclear
localisation in proliferating cells [93, 94].
3.5. Signals from the Nucleus
Nuclear factors could modulate execution of death program by different ways. While some nuclear
factors such as E2F1, STAT3, STAT5, HIF-1α,a n dN F - κB control expression of genes encoding pro- or
antiapoptotic factors, other nuclear proteins could act as nuclear transducers and inﬂuence the extrinsic
or intrinsic apoptotic signaling pathways following their relocalisation to the cytoplasm. While p73 was
suggested to exert such activity [97], the cytoplasmic accumulation of the nuclear proteins p53, p21/WAF1,
nur77, and SHP has been shown to directly affect pro- or antiapoptotic factors, and hence, apoptosis
in cancer cells [98–102]. Recent studies have identiﬁed important roles for the nuclear proteins PCNA
(proliferating cell nuclear antigen) and MNDA (myeloid nuclear differentiation antigen) in the regulation
of constitutive apoptosis in human neutrophils [55, 103].
In proliferating cells, PCNA is predominantly located in the nucleus where it inﬂuences DNA repli-
cation, transcription, cell cycle, chromosomal segregation, and DNA repair processes [104]. In neutrophils,
PCNA accumulates in cytoplasm where it physically interacts with and sequesters procaspase-3, -8, -9, and
-10 [103]. Cytoplasmic accumulation of PCNA decreases rapidly in aging neutrophils, and interestingly, it
increases in neutrophils exposed to the survival signal G-CSF [103].
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Cytoplasmic accumulation of MNDA has been reported to inﬂuence the fate of Mcl-1 both in human
neutrophilsandinHL-60cells[55].MNDA,amemberofthehumanHIN-200family,exhibitscharacteristic
nucleolar localization and is thought to be a myeloid-speciﬁc factor possibly involved in myeloid cell
differentiation [105]. MNDA relocates to the cytoplasm, and it is cleaved by caspases, presumably caspase-
3 in neutrophils undergoing constitutive apoptosis and HL-60 cells exposed to genotoxic stress [55]. MNDA
directly interacts with Mcl-1, promotes its proteasomal degradation, and consequently leads to collapse of
mitochondrial transmembrane potential [55]. Furthermore, in neutrophils from patients with severe sepsis,
cytoplasmic relocalization of MNDA is impaired which correlates with delayed apoptosis and appears to
portend a poor prognosis for septic patients. LPS, bacterial DNA, and platelet-activating factor, which
activate survival signaling circuits in neutrophils during severe sepsis, prevent cytoplasmic accumulation
of MNDA parallel with suppression of apoptosis [55]. While hindrance of mitochondrial dysfunction
and consequently attenuation of caspase-3 activation likely contribute to impaired MNDA translocation,
additional work is needed to explore the underlying molecular links. Knockdown of MNDA in HL-60 cells
rendered HL-60 cells resistant to genotoxic stress-induced apoptosis [55].
Taken together, these studies suggest a complex role for nuclear proteins in the regulation of
constitutive neutrophil apoptosis. Indeed, while MNDA relocalization to the cytoplasm facilitates apoptosis,
the cytoplasmic accumulation of PCNA is associated with delayed neutrophils apoptosis. Noticeably, the
downstream “apoptosis-controlling” proteins targeted by PCNA and MNDA are also different.
3.6. Mcl-1 Degradation
Beside speciﬁc kinases implicated in the phosphorylation of Mcl-1, the E3 ubiquitin ligase MULE (Mcl-
1 ubiquitin ligase E3) is responsible for the constitutive polyubiquitination of Mcl-1 and subsequent
proteasomal degradation [106]. GM-CSF promotion of neutrophil survival is predominantly mediated
through blocking this process [75]. Conversely, the deubiquitinase USP9X reverses polyubiquitination
of Mcl-1 and promotes its stability [107]. Since MNDA does not appear to interact with any of these
factors (unpublished observations), it is not clear how and when, during the multiple steps leading to Mcl-1
proteasomal degradation, MNDA interferes with this event. It remains to be deﬁned why a cell-speciﬁc
protein, like MNDA, exerts such a critical function on Mcl-1 turnover, while Mcl-1 is critical for survival
of many other cell types that do not express MNDA.
Mcl-1 degradation during apoptosis may be further accelerated by activation of other E3 ubiquitin
ligases and/or cleavage by other proteases [66]. For instance, caspase-3-mediated cleavage of Mcl-1 within
the N-terminus has been reported [108, 109], which may convert Mcl-1 to a proapoptotic protein [108].
Intriguingly, in high-purity human neutrophils, initial falls in Mcl-1 level precede caspase-3 activation and
apoptosis, whereas at later time points, drops in Mcl-1 can be reversed with caspase inhibition [110]. These
observations suggest that Mcl-1 may also function as an upstream regulator of caspase activation in addition
to being a target for degradation by caspases.
4. Mcl-1 AS A THERAPEUTIC TARGET
Targeting the apoptotic machinery in neutrophils has emerged as a potential approach to promote resolution
of inﬂammation. Neutrophil apoptosis is essential for their clearance from inﬂamed tissues. Apoptotic
neutrophils stop releasing proinﬂammatory mediators, secrete alpha-defensins [111], and sequester
cytokines [112, 113]. Phagocytosis of apoptotic neutrophils and other cells induces macrophages to switch
from a proinﬂammatory to a proresolution phenotype [114], thereby activating proresolution circuits [15].
The importance of Mcl-1 as a key regulator of neutrophil survival renders this protein a promising target
for therapeutic induction of apoptosis in inﬂammatory neutrophils. Indeed, therapeutic strategies to redirect
neutrophils to apoptosis appear to be mediated, at least in part, through modulation of Mcl-1.
Pharmacological inhibition of ERK1/2 and PI3K signalling has emerged as a potential resolution
therapy. PI3K has been implicated in persistence of neutrophil-mediated inﬂammation [115]. Selective
1953TheScientiﬁcWorldJOURNAL (2011) 11, 1948–1962
ERK1/2 blockade was reported to enhance resolution of inﬂammation and was linked indirectly to an
increase in neutrophil apoptosis in a mouse pleurisy model [116]. Interestingly, treatment of neutrophils
with sodium salicylate results in p38 MAPK-mediated reduction of Mcl-1 expression and acceleration of
apoptotic cell death [117]. The phosphodiesterase 4 inhibitor, rolipram, reduces neutrophil accumulation
and induces neutrophil apoptosis in LPS-induced pleurisy in mice [118]. Resolution of pleural inﬂammation
is associated with inhibition of the PI3K/Akt pathway, coinciding with decrease in Mcl-1 protein levels in
neutrophils, and can be blocked by the pan-caspase inhibitor zVAD-fmk. Although rolipram also inhibited
NF-κB activation in inﬁltrating leukocytes, this pathway does not appear to be relevant to resolution,
for other NF-κB inhibitors, pyrrolidine dithiocarbamate (PDTC), and SN50 failed to reduce neutrophil
accumulation in the pleural cavity [118].
Inhibition of survival signals generated by outside-in signalling through Mac-1 has also been impli-
cated in mediating the anti-inﬂammatory and proresolution actions of lipoxin A4 and aspirin-triggered 15-
epi-LXA4. Thus, 15-epi-LXA4 administered intravenously as a bolus injection at the peak of inﬂammation
enhances resolution of exogenous and endogenous MPO-mediated pulmonary neutrophil accumulation and
acute lung injury and improves the survival rate of mice [119]. 15-epi-LXA4 attenuates MPO activation of
ERK1/2 and PI3K and redirects neutrophils to apoptosis by decreasing Mcl-1 expression [119]. Conversely,
MPO-deﬁcient mice exhibit reduced tissue neutrophil accumulation and injury following injection of live
E. coli [120] and during ischemia/reperfusion [121]. It is not known whether MPO deﬁciency could affect
Mcl-1 expressionandthe longevityof neutrophils. Aspirin or lovastatinreductionofacidaspiration-induced
lung inﬂammation is, in part, mediated through stimulation of 15-epi-LXA4 [122, 123] though the effect
of lovastatin on neutrophil apoptosis in this model has not been investigated. In vitro, aspirin or sodium
salicylate counteracts LPS-, but not GM-CSF-mediated neutrophil survival [76] through inhibition of NF-
κB activation [124] and acceleration of Mcl-1 degradation [117, 125]. Consistently, both aspirin and sodium
salicylate increase the percentage of apoptotic neutrophils in thioglycollate-induced peritonitis [76].
Similar to lipoxins, resolvin E1 and D2, derived from the enzymatic modiﬁcation of ω-3
polyunsaturated fatty acids [15, 126], were reported to effectively attenuate excessive neutrophil trafﬁcking
in acid aspiration or E. coli-evoked pneumonia [127] and cecal ligation and puncture-induced peritonitis
[128]. The impact of resolvins on neutrophil apoptosis remains to be investigated.
Another possibility to induce neutrophil apoptosis is the use of CDK inhibitors, in particular R-
roscovitine, to accelerate Mcl-1 degradation [129]. Human neutrophils express CDK1, CDK2, and CDK5
[129, 130] though their function in terminally differentiated neutrophils is largely unknown. CDK1 phos-
phorylation of Ser64 in Mcl-1 enhances its antiapoptotic action [86] but does not appear to affect the stability
of Mcl-1 [66]. Regardless of the precise molecular mechanism of action, R-roscovitine was reported to
enhance resolution of pleural inﬂammation [129], bleomycin-induced lung injury [129], arthritis [129], and
hemorrhagic brain damage in mice [131] presumably through accelerating caspase-dependent neutrophil
apoptosis. In vitro culture of neutrophils form patients with cystic ﬁbrosis with R-roscovitine restores
impaired apoptosis to normal level [132] though the underlying mechanisms remain to be investigated.
Neutrophils may remain sensitive towards Fas ligand- or TNF-triggered apoptosis despite of suppre-
ssed intrinsic pathway. Thus, ex vivo cross-linking Fas with agonistic anti-Fas IgM on neutrophils from
severely injured patients, which express high levels of Mcl-1, was found to evoke caspase-mediated Mcl-1
cleavage and mitochondrial dysfunction [133].
While these observations clearly indicate that ablating Mcl-1 expression and/or function is sufﬁcient
to promote apoptosis in neutrophils, nonselective targeting of Mcl-1 may have potential toxicity in
lymphoid tissues, as suggested by Mcl-1 knock-out experiments [134, 135]. Selective Mcl-1 antagonism
in inﬂammatory neutrophils would likely overcome such limitations.
5. CONCLUSION
Neutrophil apoptosis has emerged as an important control point in determining the outcome of the
inﬂammatory response. Thus, suppressed neutrophil apoptosis contributes to persisting inﬂammation,
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FIGURE 1: Mcl-1 integrates survival and proapoptosis cues in human neutrophils. Mcl-1 functions as
a survival signal for human neutrophils by blocking the proapoptotic action of Bak (and/or Bim) at the
outer mitochondrial membrane. In aging neutrophils, decreases in Mcl-1 level may precede initiation of
the cell death program. At later stages, Mcl-1 is rapidly degraded by the proteasome and/or cleaved by
caspase-3. Ligation of Fas accelerates Mcl-1 proteasomal degradation. Falls in Mcl-1 lead to collapse
of mitochondrial function, and apoptosis. Cytoplasmic accumulation of the nuclear protein MNDA further
accelerates Mcl-1 degradation. Survival cues from GM-CSF, acute-phase proteins, and ligation of Mac-
1 have been reported to enhance transcription of Mcl-1, promote dissociation of Mcl-1 from Bax (and/or
Bad) in the cytoplasm and translocation of Mcl-1 to the mitochondria, and/or inhibit Mcl-1 degradation. GM-
CSF predominantly inﬂuences proteasomal degradation of Mcl-1. Blockade of survival signalling circuits
by MAPK inhibitors, lipoxin A4, or aspirin-triggered 15-epi-LXA4 redirects neutrophils to apoptosis by
decreasing Mcl-1 level. Likewise, the CDK inhibitor roscovitine evokes drops in Mcl-1 through yet undeﬁned
mechanisms. Therapeutic induction of neutrophil apoptosis through modulation of Mcl-1 expression would
contribute to clearance of emigrated neutrophils, thereby enhancing the resolution of inﬂammation.
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whereas induction of apoptosis in neutrophils exerts anti-inﬂammatory actions and enhances the resolution
of inﬂammation. We have highlighted the importance of Mcl-1 in neutrophil survival and attempted to
review the multiple levels of control of Mcl-1 expression and function as well as the intricate interplay
between survival and proapoptosis signaling circuits that determine the fate of neutrophils (Figure 1). We
also discussed that old and emerging therapeutic strategies to target neutrophils appear to act via modulation
of Mcl-1. Small molecules affecting the expression or function of Mcl-1 in a neutrophil-speciﬁc fashion
appear to be promising tools to dampen the harmful excesses of inﬂammation.
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